Study of Subcutaneous Interstitial Pressure During Sepsis (PISEP)

The pathophysiology of sepsis is characterized by the sudden onset of vasodilation and vascular permeability with capillary leakage. This leakage contributes to the development of generalized edema which is not clinically detectable below 4 litres but which becomes visible after a few days. The edema accumulates mainly at the subcutaneous level due to the high compliance of this tissue. Edema, and therefore hydrosodium overload, testifies to the severity of the inflammation. However, it could also be harmful in itself (affecting microcirculation and increasing mortality) as suggested by numerous clinical and experimental studies.

The transfer of fluids between vascular and interstitial compartments during sepsis therefore has a central role in the pathophysiology of the disease and associated mortality. These transfers are mainly controlled at the microvascular level (with constant permeability) by the difference between capillary (CP) and interstitial (IP) pressures. In healthy subjects, subcutaneous IP is discreetly negative (-1 mmHg) and varies very little. On the other hand, a sometimes drastic decrease in IP has been described in various localized and systemic inflammatory situations. These pressure variations may be explained by the collagen structure of the interstitial tissue and a change in the three-dimensional conformation of these macromolecules induced by inflammation mediators. In an animal model of sepsis, a study showed significantly lower pressure in a group of animals in endotoxic shock. IP has never been measured in humans during sepsis. The objective of this study is to analyze subcutaneous IP (SCIP) in patients with septic shock compared with controls in order to evaluate the direct role of interstitial tissue in the onset of edema during sepsis.

Study Overview

• Status: Completed
• Conditions: Patients With Septic Shock
• Intervention / Treatment: Procedure: Subcutaneous pressure measurement

• Study Type: Interventional
• Enrollment (Actual): 31
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Dijon, France, 21079
    • CHU de Dijon
  • Lyon, France, 69003
    • HCL - Hôpital Edouard Herriot

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Criteria common to both groups:

• Adult,
• Admitted within the last 24 hours in intensive care,
• Under mechanical ventilation with orotracheal intubation,
• Without clinically detectable edema (in any area)
• Patient and/or guardian and/or close relative has given written consent

Patients included in the "septic shock" arm:

• Diagnosis of septic shock as defined by the "Sepsis-3" Consensus Conference (JAMA 2016) (34): documented or highly suspected infection with SOFA ≥ 2, persistent hypotension after correction of hypovolemia requiring vasopressor administration, and serum lactate > 2 mmol/l.
• Vascular filling < 50 ml/kg

Patients included in the control arm:

• Absence of sepsis and shock from any cause:

  • PAS > 100 mmHg
  • Absence of vasopressors
  • Preserved urine > 0.5 ml/kg/h
  • Normal serum lactate
• Crystalloid infusions < 50ml/kg over the previous 12 hours

Exclusion Criteria:

• not affiliated to national health insurance
• under court protection
• pregnant or breastfeeding
• Clinical disseminated intravascular coagulation (DIC) with hemorrhagic syndrome
• Admitted after resuscitation for cardiac arrest
• Presenting cardiogenic shock
• Presenting acute pancreatitis
• Severe overall dehydration (clinical signs of dehydration and natremia > 150mmol/l)
• Presenting metformin intoxication
• In severe sepsis or septic shock for more than 24 hours,
• Dying or for whom death seems imminent (within 24 hours),
• Hypersensitivity to lidocaine and/or prilocaine or local anesthetics of the amide type or to any of the excipients of EMLAPATCH®

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Control	Procedure: Subcutaneous pressure measurement; Subcutaneous interstitial measurement at D1 and D2
Other: Septic shock	Procedure: Subcutaneous pressure measurement; Subcutaneous interstitial measurement at D1 and D2

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Value of Initial subcutaneous interstitial pressure	Measure the difference between the subcutaneous interstitial pressure of patients in septic shock compared to patients without sepsis	Day 0

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire Dijon

Study record dates

Study Major Dates

• Study Start (Actual): May 26, 2019
• Primary Completion (Actual): July 21, 2022
• Study Completion (Actual): August 9, 2022

Study Registration Dates

• First Submitted: January 21, 2019
• First Submitted That Met QC Criteria: January 24, 2019
• First Posted (Actual): January 28, 2019

Study Record Updates

• Last Update Posted (Actual): November 30, 2022
• Last Update Submitted That Met QC Criteria: November 29, 2022
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Systemic Inflammatory Response Syndrome; Inflammation; Shock; Sepsis; Shock, Septic
• Other Study ID Numbers: DARGENT 2018

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No